mdlinx mdlinx

Oncology - Pharmacology/Therapy News & Articles

Looking for the latest in oncology clinical literature? You've found the right page. MDLinx Oncology medical editors comb through the top peer-reviewed clinical journals for the articles they think will make a difference to you and your practice. You'll find them organized here by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants and the whole cancer care team can stay current on the literature as it is published.

On this page, you'll also find MDLinx exclusive content, including monthly highlights from our physician editor, D. Scott Cunningham, MD, PhD. We feature clinical pearls as well, from The Smartest Oncologist to oncology topics in The Smartest Pediatrician daily quiz challenges.

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx
New! >> Find out who is the Smartest Doc in Oncology!

Articles

Latest (10) Full Text Articles (1643) Focus on Pancreas
Ranked, sorted, and summarized by MDLinx editors from the latest literature
Topics:

461 The effect of Thespesia populnea on cisplatin induced nephrotoxicity Journal of Cancer Research and Therapeutics, April 18, 2013    Clinical Article

462 The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate Journal of Cancer Research and Therapeutics, April 18, 2013    Clinical Article

463 The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer Patients Chinese Journal of Lung Cancer, April 18, 2013    Clinical Article

464 Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas Neuro-Oncology, April 18, 2013    Review Article

465 Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin Neuro-Oncology, April 18, 2013    Review Article

466 What is the Incidence of Metastatic Lymph Node Involvement After Significant Pathologic Response of Primary Tumor Following Neoadjuvant Treatment for Locally Advanced Rectal Cancer? Annals of Surgical Oncology, April 18, 2013    Clinical Article

467 The changing paradigm of CLL management European Journal of Internal Medicine , April 17, 2013    Review Article

468 A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours European Journal of Cancer, April 17, 2013    Clinical Article

469 Preclinical Antitumor Activity of Cabazitaxel, a Semi-Synthetic Taxane Active in Taxane-Resistant Tumors Clinical Cancer Research, April 17, 2013    Clinical Article

470 Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for the KATP channel Clinical Cancer Research, April 17, 2013    Clinical Article

471 Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours European Journal of Cancer, April 17, 2013    Clinical Article

472 Chemotherapy Acts as an Adjuvant to Convert the Tumor Microenvironment into a Highly Permissive State for Vaccination-Induced Antitumor Immunity Cancer Research, April 17, 2013    Clinical Article

473 Neoadjuvant treatment for unresectable rectal cancer: An interim analysis of a multicentre randomized study Radiotherapy & Oncology, April 17, 2013    Clinical Article

474 The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias Cancer Chemotherapy and Pharmacology, April 17, 2013    Clinical Article

475 Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil Cancer Chemotherapy and Pharmacology, April 17, 2013    Clinical Article

476 Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients Cancer, April 17, 2013    Clinical Article

477 Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors Cancer Chemotherapy and Pharmacology, April 17, 2013    Clinical Article

478 Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells Oncogene, April 17, 2013    Clinical Article

479 CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy Breast Cancer Research and Treatment, April 17, 2013    Clinical Article

480 Functional Organ Preservation in Locally Advanced Laryngeal Squamous Cell Carcinoma: Is there a Role for Induction Chemotherapy Clinical Oncology, April 17, 2013    Clinical Article

50 available pages First Previous 24 25 26 27 28 29 30 31 32 33 Next Last

Clinical Pearls in Oncology

Highlights in Oncology

VEGFR-1 is a prognostic marker for HCC

As reported in the Journal of Pathology, the expression of vascular endothelial growth factor receptor (VEGFR)-1 is elevated in invasive hepatocellular cancer (HCC) specimens. In a study based on 135 HCC specimens, elevated VEGFR-1 was also associated with worse recurrence-free and overall survival.

Read the article summary

HCC risk increased in patients with AIDS

As reported in Cancer, researchers from the NCI have reported that patients with AIDS have a 4-fold increased risk of HCC compared to the general population. The study findings were based on 615,150 patients with AIDS between 1980 and 2009. The risk for HCC in patients with AIDS was essentially the same during the monotherapy/dual therapy and highly active anti-retroviral therapy eras.

Read the article summary

RAB25 is a prognostic marker for ovarian cancer

As reported in the International Journal of Cancer Research and Treatment, the pre-operative level of RAB25 is a predictor of disease-free survival (HR=18.2) and overall survival (HR=33.6) in patients with ovarian cancer. The study involved 36 and 16 women with ovarian cancer and benign tumors, respectively. The pre-operative cell-free DNA of genes (B2M, RAB25, CLDN4, and ABCF2) were measured and RAB25 was shown to be an independent prognostic factor.

Read the article summary

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Most Popular Oncology Articles

Last month's top read Top Articles of 2012

1 Enalapril And Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients with Malignant Hemopathies. The OVERCOME Trial JACC - Journal of the American College of Cardiology, April 12, 2013

2 Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia Annals of Hematology, April 9, 2013

3 A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases Clinical Cancer Research, April 5, 2013

4 Controversies of the Hormonal Conservative Treatment of Endometrial Cancer Gynecologic and Obstetric Investigation, April 12, 2013    Review Article

5 The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia Hematology, March 14, 2013

6 Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer Lung Cancer, April 3, 2013

7 Successful treatment by azacitidine therapy of intestinal Behçets disease associated with myelodysplastic syndrome International Journal of Hematology, April 2, 2013

8 Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China Cancer, April 12, 2013

9 Phase III, Multicenter, Randomized Trial of Maintenance Chemotherapy Versus Observation in Patients With Metastatic Breast Cancer After Achieving Disease Control With Six Cycles of Gemcitabine Plus Paclitaxel As First-Line Chemotherapy: KCSG-BR07-02 Journal of Clinical Oncology, April 11, 2013

10 Mammographic Breast Density Response to Aromatase Inhibition Clinical Cancer Research, March 13, 2013

11 A review of iniparib in ovarian cancer Expert Opinion on Investigational Drugs, March 14, 2013

12 Continuous treatment with new agents for newly diagnosed multiple myeloma Anti-Cancer Drugs, April 9, 2013    Evidence Based Medicine    Review Article

13 Analysis of Treatment Outcomes of Intraventricular Chemotherapy in 105 Patients for Leptomeningeal Carcinomatosis from Non-Small-Cell Lung Cancer Journal of Thoracic Oncology, April 18, 2013

14 Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis Breast Cancer Research and Treatment, April 18, 2013

15 Clinical Analysis of Gefitinib in the Treatment of Stage IV Lung Adenocarcinoma with Unknown EGFR Gene Mutations Thoracic Cancer, April 5, 2013

16 Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer Journal of Clinical Oncology, April 11, 2013

17 Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer Annals of Thoracic Medicine, April 2, 2013    Free full text

18 Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study Lung Cancer, April 1, 2013

19 The changing paradigm of CLL management European Journal of Internal Medicine , April 17, 2013    Review Article

20 90Yttrium-Ibritumomab Tiuxetan Consolidation of First Remission in Advanced-Stage Follicular Non-Hodgkin Lymphoma: Updated Results After a Median Follow-Up of 7.3 Years From the International, Randomized, Phase III First-Line Indolent Trial Journal of Clinical Oncology, April 4, 2013

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Other Topics in Oncology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow Us
Facebook

Receive free subspecialty
"5-minute updates" via email

Sign up!

Send the E-mail Newsletter to a Colleague


Send

Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More

Close